Abstract Background: There is scarce evidence verifying the impact of neuraminidase inhibitors (NAIs) in reducing influenza complications. The aim was to evaluate the available evidence from randomized-controlled trials (RCT) regarding the efficacy and safety of NAIs in reducing influenza complications. Methods: A systematic search of the literature was performed in the Cochrane Library, PubMed and Web of Science databases (2006–2019). Eligibility criteria were RCT that enrolled patients of any age or clinical severity with seasonal influenza (H₁N₁, H₃N₂, or B) or influenza-like syndrome and receiving NAIs comparing to placebo therapy. Results: Eighteen RCTs (9004 patients) were included: nine focused on oral oseltamivir, six on inhaled ...
Objective: To review the clinical effectiveness of oseltamivir and zanamivir for the treatment and p...
BACKGROUND: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, ...
Background: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, ...
Background: Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies ...
Introduction: Influenza represents a major public health threat worldwide. Implementation of good pe...
Background Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies f...
Background Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies f...
BACKGROUND: Neuraminidase inhibitors (NI) are recommended for use against influenza and its complica...
PURPOSE OF REVIEW: Seasonal and pandemic influenza are major causes of morbidity and mortality globa...
PURPOSE OF REVIEW: Seasonal and pandemic influenza are major causes of morbidity and mortality globa...
PURPOSE OF REVIEW: Seasonal and pandemic influenza are major causes of morbidity and mortality globa...
PURPOSE OF REVIEW: Seasonal and pandemic influenza are major causes of morbidity and mortality globa...
Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies for treating...
Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies for treating...
Objective: To review the clinical effectiveness of oseltamivir and zanamivir for the treatment and p...
Objective: To review the clinical effectiveness of oseltamivir and zanamivir for the treatment and p...
BACKGROUND: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, ...
Background: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, ...
Background: Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies ...
Introduction: Influenza represents a major public health threat worldwide. Implementation of good pe...
Background Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies f...
Background Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies f...
BACKGROUND: Neuraminidase inhibitors (NI) are recommended for use against influenza and its complica...
PURPOSE OF REVIEW: Seasonal and pandemic influenza are major causes of morbidity and mortality globa...
PURPOSE OF REVIEW: Seasonal and pandemic influenza are major causes of morbidity and mortality globa...
PURPOSE OF REVIEW: Seasonal and pandemic influenza are major causes of morbidity and mortality globa...
PURPOSE OF REVIEW: Seasonal and pandemic influenza are major causes of morbidity and mortality globa...
Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies for treating...
Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies for treating...
Objective: To review the clinical effectiveness of oseltamivir and zanamivir for the treatment and p...
Objective: To review the clinical effectiveness of oseltamivir and zanamivir for the treatment and p...
BACKGROUND: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, ...
Background: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, ...